| Active substance | ravulizumab |
| Holder | Alexion Pharma Belgium |
| Status | Running |
| Indication | treatment of Paroxysmal Nocturnal Haemoglobinuria in patients who completed the Open Label Extensions of the phase III studies ALXN1210-PNH-301 (EudraCT Nr: 2016-002025-11) or ALXN1210-PNH-303 (EudraCT Nr: 2017-002370-39) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 02/02/2023 |